The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.

about

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.

Item

http://www.wikidata.org/entity/Q47193937

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The clinical efficacy of Afati ...... exon 19 or exon 21 mutations.

@en

The clinical efficacy of Afati ...... exon 19 or exon 21 mutations.

@nl

type

Item

label

The clinical efficacy of Afati ...... exon 19 or exon 21 mutations.

@en

The clinical efficacy of Afati ...... exon 19 or exon 21 mutations.

@nl

prefLabel

The clinical efficacy of Afati ...... exon 19 or exon 21 mutations.

@en

The clinical efficacy of Afati ...... exon 19 or exon 21 mutations.

@nl

P1476

The clinical efficacy of Afati ...... exon 19 or exon 21 mutations.

@en

P2093

Chih-Jen Yang

http://www.w3.org/2001/XMLSchema#string

Inn-Wen Chong

http://www.w3.org/2001/XMLSchema#string

Jen-Yu Hung

http://www.w3.org/2001/XMLSchema#string

Jui-Feng Hsu

http://www.w3.org/2001/XMLSchema#string

Mei-Hsuan Lee

http://www.w3.org/2001/XMLSchema#string

Ming-Ju Tsai

http://www.w3.org/2001/XMLSchema#string

Ming-Shyan Huang

http://www.w3.org/2001/XMLSchema#string

Ta-Chih Liu

http://www.w3.org/2001/XMLSchema#string

Ying-Ming Tsai

http://www.w3.org/2001/XMLSchema#string

Yu-Chen Tsai

http://www.w3.org/2001/XMLSchema#string

P2860

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

P2888

s40360-017-0190-1

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40360-017-0190-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1099598150

http://www.w3.org/2001/XMLSchema#string

P698

29237484

http://www.w3.org/2001/XMLSchema#string

P932

5729426

http://www.w3.org/2001/XMLSchema#string